# HYDROxychloroquine in Syndrome Primary AntiPhospholipid

> **NCT04275778** · PHASE2 · WITHDRAWN · sponsor: **Assistance Publique - Hôpitaux de Paris**

## Conditions studied

- Antiphospholipid Syndrome in Pregnancy
- Anticoagulants

## Interventions

- **DRUG:** Plaquenil 200Mg Tablet
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04275778
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-07-09
- **Primary completion:** 2024-10-02
- **Final completion:** 2025-10-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was terminated following revisions to the diagnostic criteria defining the target pathology, which significantly impacted the study design
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04275778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04275778, "HYDROxychloroquine in Syndrome Primary AntiPhospholipid". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04275778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*